Filing exhibits
- 8-K Current report
- 2.1 Agreement and Plan of Merger and Reorganization Among VENETIAN-1 Acquisition Corp, Lomond Acquisition Corp. and Lomond Therapeutics, Inc
- 3.1 Certificate of Merger Relating to the Merger of Lomond Acquisition Corp. with and into Lomond Therapeutics, Inc., Filed with the Secretary of State of the State of Delaware on November 1, 2024
- 3.2 Amended and Restated Certificate of Incorporation, Filed with the Secretary of State of the State of Delaware on November 1, 2024
- 3.3 Amended and Restated Bylaws
- 4.1 Form of Placement Agent Warrant
- 4.2 Form of Simple Agreement for Future Equity, Dated August 27, 2024
- 4.3 Form of Simple Agreement for Future Equity, Dated October 17, 2024
- 10.1 Administrative Services & Co-employment Agreement, Dated October 18, 2024, by and Between Abet Solutions Inc. and Lomond Therapeutics, Inc
- 10.2 Consulting Agreement with Iain Dukes, Dated As of November 1, 2024
- 10.3 Consulting Agreement with Nikolay Savchuk, Dated As of November 1, 2024
- 10.4 Form of Pre-merger Indemnification Agreement
- 10.5 Subscription Agreement, Dated November 1, 2024, by and Between the Company and the Parties Thereto
- 10.6 Registration Rights Agreement, Dated November 1, 2024, by and Between the Company and the Parties Thereto
- 10.7 2022 Equity Incentive Plan of Eilean Therapeutics, LLC and Form of Award Agreements Thereunder
- 10.8 Lomond Therapeutics, Inc. 2024 Stock Plan and Form of Award Agreements Thereunder
- 10.9 Lomond Therapeutics Holdings, Inc. 2024 Equity Incentive Plan and Form of Award Agreements Thereunder
- 10.10 Form of Indemnification Agreement
- 10.11 License Agreement, Dated As of October 17, 2024, by and Between Lomond Therapeutics, Inc. and Eil Therapeutics, Inc
- 10.12 Promissory Note, Dated As of October 17, 2024, by and Between Lomond Therapeutics, Inc. and Eil Therapeutics, Inc
- 10.13 License Agreement, Dated As of October 17, 2024, by and Between Lomond Therapeutics, Inc. and Bala Therapeutics, Inc
- 10.14 Promissory Note, Dated As of October 17, 2024, by and Between Lomond Therapeutics, Inc. and Bala Therapeutics, Inc
- 10.15 Promissory Note, Dated As of May 2, 2022, by and Between Lomond Therapeutics, Inc. and Dinas Therapeutics, Inc
- 10.16 Promissory Note, Dated As of June 21, 2022, by and Between Lomond Therapeutics, Inc. and Dinas Therapeutics, Inc
- 10.17 Promissory Note, Dated As of December 1, 2023, by and Between Lomond Therapeutics, Inc. and Eil Therapeutics, Inc
- 10.18 Promissory Note, Dated As of January 5, 2023, by and Between Lomond Therapeutics, Inc. and Eil Therapeutics, Inc
- 10.19 Assignment and Consent Agreement, Dated As of December 7, 2023, by and Among Lomond Therapeutics, Inc., Eilean Therapeutics, LLC. and Eil Therapeutics, Inc
- 10.20 Assignment and Consent Agreement, Dated As of December 7, 2023, by and Among Lomond Therapeutics, Inc., Eilean Therapeutics, LLC. and Dinas Therapeutics, Inc
- 10.21 Form of Lock-up Agreement Entered into Between the Company and the Parties Thereto
- 16.1 Letter from Grassi & Co., Cpas, P.C. As to the Change In Certifying Accountant, Dated November 7, 2024
- 21.1 Subsidiaries of the Registrant
- 99.1 Audited Financial Statements of Lomond Therapeutics, Inc., As of and for the Years Ended December 31, 2022 and 2023
- 99.2 Unaudited Financial Statements of Lomond Therapeutics, Inc., As of and for the Six Months Ended June 30, 2024
- 99.3 Unaudited Pro Forma Combined Financial Statements
- 99.4 Press Release Dated November 4, 2024
- Download Excel data file
- View Excel data file
Table of Contents